|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
4
|
|
pubmed:dateCreated |
1995-10-26
|
|
pubmed:abstractText |
Hepatic arterial infusion of 5-fluoro-2-deoxyuridine (FUdR) is associated with a 60% response rate among previously untreated patients who have hepatic-metastatic colorectal cancer. One obstacle to further dose escalation has been concomitant hepatic toxicity. We are evaluating a FUdR-containing chemotherapeutic emulsion to further dose intensify therapy without associated toxicity.
|
|
pubmed:grant |
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Jul
|
|
pubmed:issn |
1068-9265
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
2
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
N
|
|
pubmed:pagination |
351-9
|
|
pubmed:dateRevised |
2007-11-14
|
|
pubmed:meshHeading |
pubmed-meshheading:7552626-Aged,
pubmed-meshheading:7552626-Antimetabolites, Antineoplastic,
pubmed-meshheading:7552626-Colorectal Neoplasms,
pubmed-meshheading:7552626-Emulsions,
pubmed-meshheading:7552626-Female,
pubmed-meshheading:7552626-Floxuridine,
pubmed-meshheading:7552626-Hepatic Artery,
pubmed-meshheading:7552626-Humans,
pubmed-meshheading:7552626-Infusions, Intra-Arterial,
pubmed-meshheading:7552626-Liver Neoplasms,
pubmed-meshheading:7552626-Male,
pubmed-meshheading:7552626-Middle Aged,
pubmed-meshheading:7552626-Treatment Outcome
|
|
pubmed:year |
1995
|
|
pubmed:articleTitle |
Treatment of hepatic-metastatic colorectal cancer with a chemotherapeutic emulsion: interim results of a phase I trial.
|
|
pubmed:affiliation |
Department of Surgery, University of Pittsburgh Medical Center, PA 15213, USA.
|
|
pubmed:publicationType |
Journal Article,
Clinical Trial,
Research Support, U.S. Gov't, P.H.S.,
Clinical Trial, Phase I
|
